Hepatitis C: Therapeutic perspectives

FORUM - Trends in Experimental and Clinical Medicine

Volumn 11, Issue 2, 2001, Pages 154-162

  Cornberg, Markus ^a   Wedemeyer, Heiner ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Future therapies; Hepatitis C; IFN ; PEG IFN; Protease inhibitor

Indexed keywords

ALPHA INTERFERON; AMANTADINE; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; INTERLEUKIN 10; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 12; RIBAVIRIN; RIBOZYME; RNA DIRECTED RNA POLYMERASE; RNA HELICASE; SERINE PROTEINASE; THYMOSIN; URSODEOXYCHOLIC ACID; VIRUS PROTEIN;

ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION CONTROL; SIDE EFFECT; VACCINATION; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERON-ALPHA; RIBAVIRIN; RNA, CATALYTIC; TREATMENT OUTCOME; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 0035727820     PISSN: 11218142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
2. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
3. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
4. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials
5. Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated? An analysis of personal experiences and review of the literature
6. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
7. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa
8. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model
9. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C
10. Multicenter, randomized, controlled trial comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa-2b plus ribavirin
11. The pharmacokinetic behavior of pegylated (40kDa) interferon alfa-2a (PEGASYSΤM) in chronic hepatitis C patients after multiple dosing
12. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data
13. Clearance of Pegylated (40KDA) interferon alfa-2a (PEGASYS) is primarily hepatic
14. Peginterferon alfa-2a in patients with chronic hepatitis C
15. Pegylated interferon alfa-2b (PEG-INTRON) monotherapy is superior to interferon alfa-2b (INTRON A) for the treatment of chronic hepatitis C
16. Peginterferon alfa-2a in patients with chronic hepatitis C and Cirrhosis
17. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
18. Pegylated (40kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: Efficacy and safety results from a Phase III, randomized, actively controlled, multicenter study
19. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon
20. Comparison of the in vitro host range of recombinant met-interferon- con1, interferon-alpha 2b, and interferon-beta
21. A comparison of interferon-Con1 with natural recombinant interferons-alpha: Antiviral, antiproliferative, and natural killer-inducing activities
22. Consensus interferon induces peak mRNA accumulation at lower concentrations than interferon-alpha 2a
23. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial
24. Re-treatment of chronic hepatitis C with consensus interferon
25. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C
26. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders
27. Interferon induction plus ribavirin and amantadine as a novel approach for treatment of interferon nonresponder chronic hepatitis C patients
28. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C
29. Randomized, placebo-controlled, double-blind trial with interferon-α (IFN-α) with and without amantadinesulfate in primary IFN-α non-responders with chronic hepatitis C
30. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide
31. Structure of the hepatitis C virus RNA helicase domain
32. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus
33. Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwinding duplex RNA
34. A potential therapeutic application of hairpin ribozymes: In vitro and in vivo studies of gene therapy for hepatitis C virus infection
35. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes
36. Effect of immune globulin on the prevention of experimental hepatitis C virus infection
37. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B
38. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C
39. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders
40. A pilot study of the CY 1899 T-cell vaccine in subjects chronically infected with hepatitis B virus